University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Thierry Jahan

Thierry Jahan, M.D.

Lung cancer specialist

Dr. Thierry M. Jahan specializes in the treatment of lung cancer, mesothelioma, sarcomas and endocrine tumors and the use of multiple treatments. In addition to caring for patients, Jahan is involved in studying new treatments for malignancies related to the chest. His research focuses on treatments for the management of lung cancer and malignant mesothelioma.

Jahan earned a medical degree from George Washington University in Washington, D.C. He completed an internship, residency and fellowship in medicine at Cedars Sinai Medical Center in Los Angeles and then completed a fellowship in hematology and oncology at UCSF, before joining the faculty in 1994. He is the recipient of the Medical Housestaff Outstanding Teacher Award at UCSF Medical Center at Mount Zion. He also is member of numerous professional societies, including the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer and the Association of Northern California Oncologists. He is an associate professor of medicine at UCSF.

Clinics

Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-9525

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Thierry Jahan

Additional Languages

French
Russian
Spanish

Education

George Washington University 1987

Residencies

Cedars-Sinai Los Angeles, Internal Medicine 1990

Fellowships

UCSF, Hematology/Oncology 1994

Selected Research and Publications

  1. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M. Small cell lung cancer. J Natl Compr Canc Netw. 2013 Jan 1; 11(1):78-98.
  2. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct 1; 10(10):1236-71.
  3. Gilbertson-White S, Aouizerat BE, Jahan T, Paul SM, West C, Schumacher K, Dodd MJ, Rabow M, Abu Raddaha AH, Miaskowski C. Determination of cutpoints for low and high number of symptoms in patients with advanced cancer. J Palliat Med. 2012 Sep; 15(9):1027-36.
  4. Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012 Oct; 78(1):57-62.
  5. Yom SS, Chen CP, Jahan TM, Jablons DM. One size does not fit all lung cancer patients. J Thorac Oncol. 2012 May; 7(5):945.
  6. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012 May 1; 30(13):1447-55.
  7. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
  8. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012 Jan; 10(1):26-41.
  9. Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
  10. Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS. Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11):1857-64.
  11. Blakely C, Jahan T. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011 Oct; 11(10):1607-18.
  12. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small cell lung cancer. J Natl Compr Canc Netw. 2011 Oct; 9(10):1086-113.
  13. Cataldo JK, Jahan TM, Pongquan VL. Lung cancer stigma, depression, and quality of life among ever and never smokers. Eur J Oncol Nurs. 2012 Jul; 16(3):264-9.
  14. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care. 2011 Mar; 9(1):81-102.
  15. Cataldo JK, Slaughter R, Jahan TM, Pongquan VL, Hwang WJ. Measuring stigma in people with lung cancer: psychometric testing of the cataldo lung cancer stigma scale. Oncol Nurs Forum. 2011 Jan; 38(1):E46-54.
  16. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov; 8(11):1302-15.
  17. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801.
  18. Kim E, Jahan T, Aouizerat BE, Dodd MJ, Cooper BA, Paul SM, West C, Lee K, Swift PS, Wara W, Miaskowski C. Differences in symptom clusters identified using occurrence rates versus symptom severity ratings in patients at the end of radiation therapy. Cancer Nurs. 2009 Nov-Dec; 32(6):429-36.
  19. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
  20. Kim E, Jahan T, Aouizerat BE, Dodd MJ, Cooper BA, Paul SM, West C, Lee K, Swift PS, Wara W, Miaskowski C. Changes in symptom clusters in patients undergoing radiation therapy. Support Care Cancer. 2009 Nov; 17(11):1383-91.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California